$511 Million is the total value of Opaleye Management Inc.'s 55 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| OCUL | OCULAR THERAPEUTIX INC | $45,540,000 | -8.6% | 5,984,200 | 0.0% | 8.91% | -11.5% | |
| ETON | ETON PHARMACEUTICALS INC | $28,756,000 | +45.0% | 3,640,000 | 0.0% | 5.62% | +40.4% | |
| CDXS | CODEXIS INC | $16,436,000 | +2.2% | 1,400,000 | 0.0% | 3.21% | -1.1% | |
| EIDX | EIDOS THERAPEUTICS INC | $15,945,000 | +9.0% | 315,550 | 0.0% | 3.12% | +5.5% | |
| DCPH | DECIPHERA PHARMACEUTICALS IN | $11,389,000 | -12.9% | 222,000 | 0.0% | 2.23% | -15.7% | |
| FBIO | FORTRESS BIOTECH INC | $10,264,000 | 0.0% | 3,830,000 | 0.0% | 2.01% | -3.2% | |
| MYOV | MYOVANT SCIENCES LTD | $9,589,000 | -31.9% | 682,500 | 0.0% | 1.88% | -34.0% | |
| CERC | CERECOR INC | $7,678,000 | -12.4% | 3,372,500 | 0.0% | 1.50% | -15.2% | |
| BHVN | BIOHAVEN PHARMACEUTICAL HLDG | $7,434,000 | -11.1% | 114,350 | 0.0% | 1.45% | -13.9% | |
| MEIP | MEI PHARMA INC | $4,855,000 | -24.4% | 1,556,000 | 0.0% | 0.95% | -26.8% | |
| CDTX | CIDARA THERAPEUTICS INC | $2,766,000 | -22.8% | 970,664 | 0.0% | 0.54% | -25.2% | |
| BLRX | BIOLINERX LTDsponsored ads | $33,000 | +13.8% | 16,667 | 0.0% | 0.01% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.